While overexpressing the VIVIT peptide blocked NFAT cancer signaling in glioma cells, delivering it via cell-penetrating peptides (Sim-2 or 11R) failed to reproduce the effect, highlighting a key challenge in peptide-based cancer therapy.
CPP delivery failedDespite working when expressed intracellularly, VIVIT conjugated to two different cell-penetrating peptides could not inhibit NFAT in glioma cells
What the researchers found
VIVIT-GFP overexpression successfully inhibited NFAT signaling in glioma cells, but neither Sim2-VIVIT nor 11R-VIVIT cell-penetrating peptide conjugates could reproduce this effect, indicating CPP delivery is insufficient for NFATc3-expressing gliomas.
Why it matters
This study reveals an important limitation of cell-penetrating peptide drug delivery: even when a peptide works inside cells, getting enough of it there via CPPs may not be sufficient. For glioma, dual-specificity blocking peptides may be needed.
The numbers in context
VIVIT-GFP decreased NFAT activity and endogenous target genes; Sim-2-VIVIT: no activity; 11R-VIVIT: no NFAT inhibition; NFATc3 has 2 calcineurin docking sites
How the study worked
In vitro study in human glioma cell lines. VIVIT expressed as GFP fusion protein (intracellular) or conjugated to CPPs Sim-2 and 11R (extracellular delivery). NFAT expression, phosphorylation, localization, and transcriptional activity measured.
Who was studied
Human glioma cell lines (high NFATc3 expression)
What this study cannot tell us
In vitro only with glioma cell lines. The negative CPP result may be specific to these peptide-target combinations. Alternative CPPs or delivery methods were not tested. Dosing and timing optimization may have been insufficient.
How to read the evidence
Low evidence grade: in vitro study with a primarily negative result regarding CPP delivery. Important for understanding limitations of peptide delivery approaches.
When this study was published
Published in 2021. CPP delivery optimization and alternative intracellular delivery strategies continue to evolve.
The bigger picture
This negative result is valuable for peptide therapy development. It demonstrates that intracellular targets like NFAT cannot always be reached effectively with CPPs, and that some protein-protein interactions require more sophisticated blocking strategies than single-site peptide inhibitors.
Questions still open
- Could dual-specificity peptides blocking both calcineurin docking sites on NFATc3 succeed where VIVIT alone failed?
- Would alternative CPPs or nanoparticle delivery systems improve VIVIT delivery to glioma cells?
- Is NFATc3 a viable therapeutic target in glioma if better delivery methods are developed?
Common questions
Why did the cell-penetrating peptide approach fail?
Does this mean peptide therapies can't work for brain cancer?
Read the original research
Delivery of the VIVIT Peptide to Human Glioma Cells to Interfere with Calcineurin-NFAT Signaling.
Molecules (Basel, Switzerland), 26(16)
Citation
Ellert-Miklaszewska, Aleksandra; Szymczyk, Agata; Poleszak, Katarzyna; Kaminska, Bozena. (2021). Delivery of the VIVIT Peptide to Human Glioma Cells to Interfere with Calcineurin-NFAT Signaling.. Molecules (Basel, Switzerland), 26(16). https://doi.org/10.3390/molecules26164785